



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/736,227	12/15/2003	Jonathan Alexander Terrett	2543-1-033	3125

23565 7590 01/30/2007
KLAUBER & JACKSON
411 HACKENSACK AVENUE
HACKENSACK, NJ 07601

EXAMINER

HARRIS, ALANA M

ART UNIT	PAPER NUMBER
----------	--------------

1643

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	01/30/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/736,227

Applicant(s)

TERRETT, JONATHAN
ALEXANDER

Examiner

Alana M. Harris, Ph.D.

Art Unit

1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3, 17-19 and 21 is/are pending in the application.
- 4a) Of the above claim(s) 4-16 and 20 is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-3, 17-19 and 21 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☒ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|--|
| <p>1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)</p> <p>2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948)</p> <p>3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>07/06/2004</u>.</p> | <p>4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.</p> <p>5) <input type="checkbox"/> Notice of Informal Patent Application</p> <p>6) <input type="checkbox"/> Other: ____.</p> |
|--|--|

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of Group I (claims 1-3, 17-19 and 21) in the reply filed on November 13, 2006 is acknowledged. The traversal is on the ground(s) that Group III (claim 7), drawn to a method is related to the elected Group and a search would be established in the identical classes and examination of the two aforementioned Groups can be made without serious burden, see page 4 of the Remarks. This is not found persuasive because a product and a method of using a product are patentably distinct inventions as set forth in the Requirement mailed October 13, 2006.

The requirement is still deemed proper and is therefore made FINAL.

2. Claims 1-21 are pending.

Claims 4-16 and 20, drawn to non-elected inventions are withdrawn from examination.

Claims 1-3, 17-19 and 21 are examined on the merits.

Priority

3. Applicant is advised of possible benefits under 35 U.S.C. 119(a)-(d), wherein an application for patent filed in the United States may be entitled to the benefit of the filing date of a prior application filed in a foreign country.

Art Unit: 1643

Acknowledgment is made of applicant's claim for foreign priority based on an application filed in Great Britain on June 14, 2002. It is noted, however, that applicant has not filed a certified copy of the United Kingdom 0114643.0 (filed June 15, 2001) application or the United Kingdom 0205264.5 (filed March 6, 2002) as required by 35 U.S.C. 119(b). Consequently, the priority date afforded to the claims is the date of the PCT/GB02/02782 filed June 14, 2002.

Specification

4. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code, see page 3, section 0009 for example. Applicant is required to review the entire specification and delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

Claim Objections

5. Claims 1, 17 and 19 are objected to because of the following informalities: they read on non-elected subject matter. Correction is required.

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1643

7. Claims 1-3, 17-19 and 21 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The written description in this case only sets forth SEQ ID NO: 1 as a BCMP 101 polypeptide, see page 1, section 0002; page 3, sections 0010 and 0014 for example.

Vas-Cath Inc. V. Mahurkar, 19 USPQ2d 1111, clearly states that “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116). Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 USC 112 is severable from its enablement provision (see page 115).

Applicants are not required to disclose every species encompassed by a genus. For example as indicated in *The Regents of the University of California v. Eli Lilly* (43 USPQ2d 1398-1412), the description of a genus is achieved by the recitation of a representative number of DNA molecules, usually defined by a nucleotide sequence, falling within the scope of the claimed genus. At section B(1), the court states that “An adequate written description of a DNA...‘requires a precise definition, such as by structure, formula, chemical name, or physical properties’, not a mere wish or plan for

Art Unit: 1643

obtaining the claimed chemical invention”.

Applicants broadly claim a polypeptide, as well as derivatives, fragments and amino acid sequences with less than 100% sequence identity to SEQ ID NO: 1 with no corresponding structure and function. However, Applicants are not entitled, nor is the specification enabled for the use of all DTD proteins and antibodies specific for said an undefined and uncharacterized fragments of SEQ ID NO: 1. Applicant is only in possession of one species of a BCMP 101 protein, which is SEQ ID NO: 1, see page 3 of the specification, section 0009. Applicants are not permitted to claim all variants, fragments and mutants of SEQ ID NO: 1 that are encompassed by the claims, hence not entitled to the wide breadth of the claims at issue. There is no disclosure, beyond the mention of SEQ ID NO: 1 as a BCMP 101 protein made in the specification. There is no description of the sites at which variability may be tolerated and there is no information regarding the relation of structure to function. Structural features that could distinguish the compounds in the genus from others excluded are missing from the disclosure.

This is insufficient to support the generic claims as provided by the Interim Written Description Guidelines published in the June 15, 1998 Federal Register at Volume 63, Number 114, pages 32639-32645.

8. Claims 1-3, 17-19 and 21 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a composition for treating breast cancer comprising administering a polypeptide identified as SEQ ID NO: 1, does not

Art Unit: 1643

reasonably provide enablement for a composition for the prevention of any cancer with SEQ ID NO: 1, nor variants and mutants of said sequence. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

Applicants' specification does not establish a method for preventing cancer using SEQ ID NO: 1 or the undefined and uncharacterized fragments and derivatives of SEQ ID NO: 1. Applicants do provide seven examples on pages 29-35, however none exemplify preventing any disease. The intended use of the polypeptide listed in the specification is not commensurate in scope with claims, particularly the method of preventing a cancer with SEQ ID NO: 1 and fragments and derivatives, thereof.

There is no guidance in the specification as to how to determine and select a population of individuals, which may or may not eventually have cancer. Preventing a disease is just as complex a process. It is not clear what parameters one skilled in the art would use in order to identify a population of subjects in which cancer could be prevented. It is also not clear what symptoms one of skill in the art would need to identify before possibly treating a patient. While it is art known that clinicians are capable of implementing both screening and surveillance and the type of screening test used and the intervals at which it is performed are based on risk stratification, which also serves as the basis for selecting potential candidates for possible prevention. However, like most screening procedures determining whether a population will eventually be struck with a disease is not fool proof. There is insufficient evidence provided enabling one of ordinary skill in the art to determine susceptible cancer

Art Unit: 1643

candidates within a population. The specification provides neither guidance on nor exemplification of identifying a population of people who may eventually have a tumor. Furthermore, if such a group was identified there is insufficient evidence provided that the tumor growth would be inhibited with the administration of SEQ.ID NO: 1.

There would also need to be some valid amount of direction or guidance, as well as presence or absence of working examples presented in the specification that would enable one skilled in the art to perform the method as presented in the recited claims. It appears that undue experimentation would be required of one skilled in the art to practice the instant claimed invention using the teachings of the specification. See Ex parte Forman, 230 USPQ 546 BPAI, 1986.

Claim Rejections - 35 USC § 102

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

10. Claims 1-3, 17-19 and 21 are rejected under 35 U.S.C. 102(e) as being anticipated by U.S. Patent Application Publication number US2003/0092898 A1 (filed February 12, 2002).

Applicant has not perfected the claim to foreign priority. Upon perfection of foreign priority including certified copies of the English language translations of the foreign priority documents, this rejection may be withdrawn.

U.S. Patent Application Publication number US2003/0092898 discloses Sequence 267 a derivative and a fragment of Applicants' SEQ ID NO: 1, see attached database sheet. The disclosed amino acid sequence can be provided in a fusion protein, as well as in pharmaceutical compositions for breast cancer treatment, see abstract; page 27, sections 0244-0248; and page 42, sections 0424, 0426 and 0427.

11. Claims 1, 3, 17-19 and 21 are rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent number 5,776,687 (issued July 7, 1998). U.S. Patent #5,776,687 discloses Sequence 12, which is a derivative and a fragment of SEQ ID NO: 1, see attached database. The disclosed amino acid sequence can be provided in a fusion protein, as well as in pharmaceutical compositions for breast cancer treatment, see column 5, lines 27-column 6, line 2; and column 6, lines 38-57.

12. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (571)272-0831. The Examiner works a flexible schedule, however she can normally be reached between the hours of 7:30 am to 6:30 pm, with alternate Fridays off.


If attempts to reach the Examiner by telephone are unsuccessful, the examiner's supervisor, Larry R. Helms, Ph.D. can be reached on (571) 272-0832. The fax phone

Art Unit: 1643

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ALANA M. HARRIS, PH.D.
PRIMARY EXAMINER


Alana M. Harris, Ph.D.
22 January 2007